
Co-Diagnostics (CODX) Stock Forecast & Price Target
Co-Diagnostics (CODX) Analyst Ratings
Bulls say
Co-Diagnostics Inc. is positioned positively within the expanding market for respiratory infectious disease diagnostics, particularly in the Middle East, driven by significant investments in the Kingdom of Saudi Arabia. The establishment of a joint venture with Arabian Eagle Manufacturing to commercialize Co-Dx technologies across the region signals strategic growth opportunities, although immediate financial impacts may be limited. Additionally, the company's development of proprietary instruments for its Co-Dx PCR platform enhances its offerings and may lead to improved operational efficiency and potential market differentiation moving forward.
Bears say
Co-Diagnostics Inc faces significant risks that could hinder its financial performance and overall viability, including potential failures in clinical evaluations, regulatory clearance, and commercial success against competition, all leading to potential dilution issues for shareholders. In the third quarter of 2025, the company reported a modest revenue of $145,000 while incurring a substantial net loss of $5.9 million, equating to a loss of $0.16 per share. These financial metrics, coupled with concerns about future fundraising becoming more dilutive and less favorable, contribute to a negative outlook for Co-Diagnostics's stock.
This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Co-Diagnostics (CODX) Analyst Forecast & Price Prediction
Start investing in Co-Diagnostics (CODX)
Order type
Buy in
Order amount
Est. shares
0 shares